Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3811027 | 1.00 | ALDH1A1 (0.40) | ALDH1A1HTTLMNAKMT2AMEN1 | |
| SCHEMBL14559172 | 0.86 | TDP1 (0.40) | ALDH1A1HTTLMNAKMT2AMEN1 | |
| SCHEMBL14517799 | 0.85 | ALDH1A1 (0.41) | ALDH1A1HTTLMNAKMT2AMEN1 | |
| SCHEMBL6915551 | 0.84 | FFAR1 (0.48) | ALDH1A1KMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL10062805 | 0.82 | NPC1 (0.43) | ALDH1A1HTTLMNAKMT2AMEN1 | |
| SCHEMBL3810953 | 0.82 | NPC1 (0.43) | ALDH1A1HTTLMNAKMT2AMEN1 | |
| SCHEMBL14543247 | 0.80 | CA2 (0.38) | ALDH1A1HTTLMNAKMT2AMEN1 | |
| SCHEMBL3811748 | 0.76 | KMT2A (0.37) | ALDH1A1HTTLMNAKMT2AMEN1 | |
| SCHEMBL10029122 | 0.76 | ALDH1A1 (0.41) | ALDH1A1HTTLMNAKMT2AMEN1 | |
| SCHEMBL10029149 | 0.74 | ALDH1A1 (0.43) | ALDH1A1HTTLMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108069887-B | Preparation method of (R) -bicalutamide intermediate | 山西振东制药股份有限公司 | 2021-04-20 | — | — | CN | claimed |
| CN-108069887-B | Preparation method of (R) -bicalutamide intermediate | 山西振东制药股份有限公司 | 2021-04-20 | — | — | CN | disclosed |
| CN-108069887-B | Preparation method of (R) -bicalutamide intermediate | 山西振东制药股份有限公司 | 2021-04-20 | — | — | CN | disclosed |
| US-20170101384-A1 | ANDROGEN RECEPTOR ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-04-13 | — | — | US | disclosed |
| US-20170101384-A1 | ANDROGEN RECEPTOR ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-04-13 | — | — | US | disclosed |
| WO-2015196144-A2 | ANDROGEN RECEPTOR ANTAGONISTS | ENGLAND PAMELA M (US) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101384-A1 | ANDROGEN RECEPTOR ANTAGONISTS | AR, LHCGR, FSHR | ALDH1A1 1171/4885HTT 4742/4885LMNA 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.